Dr. Brooke E. Daniel, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Tennessee, Hsc, College of Medicine (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 794
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: University of Tennessee, Hsc, College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TN license MD39893 · GA license 056540
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Healthcare System, Inc Chattanooga, TN
- Erlanger Medical Center Chattanooga, TN
- Commonspirit-Memorial Hospital-North Georgia Ringgold, GA
Medical groups
- Tennessee Oncology PLLC (358 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 794
- Services billed
- 144,675
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 19,530 | 167 |
| Injection, ferric carboxymaltose, 1 mg | 18,750 | 17 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,648 | 50 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,299 | 422 |
| Insertion of needle into vein for collection of blood sample | 1,128 | 430 |
| Blood test, comprehensive group of blood chemicals | 1,121 | 419 |
| Established patient office or other outpatient visit, 30-39 minutes | 689 | 301 |
| Administration of chemotherapy into vein, 1 hour or less | 270 | 76 |
| Injection of drug or substance under skin or into muscle | 209 | 39 |
| Injection, granisetron hydrochloride, 100 mcg | 200 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Chattanooga, TN | 171 |
| Tamoxifen Citrate Other prescribers in Chattanooga, TN | 152 |
| Ondansetron Odt (ondansetron) Other prescribers in Chattanooga, TN | 95 |
| Exemestane | 59 |
| Letrozole Other prescribers in Chattanooga, TN | 48 |
| Calquence (acalabrutinib maleate) | 47 |
| Revlimid (lenalidomide) | 38 |
| Acyclovir Other prescribers in Chattanooga, TN | 36 |
| Jakafi (ruxolitinib phosphate) | 33 |
| Alendronate Sodium Other prescribers in Chattanooga, TN | 33 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 16 payments worth $411 in total to this clinician.
| Kite Pharma, Inc. | $111 |
|---|---|
| Novartis Pharmaceuticals Corporation | $74.09 |
| Gilead Sciences, Inc. | $48.59 |
| Adc Therapeutics America, Inc. | $38.67 |
| Celgene Corporation | $27.45 |
| Incyte Corporation | $25.59 |
| Tersera Therapeutics LLC | $23.87 |
| Astellas Pharma US Inc | $22.32 |
| Food and Beverage | $398 |
|---|---|
| Education | $12.91 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Mar 14, 2025 | Education VYNDAMAX · CARDIOVASCULAR · in-kind | $12.91 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 7 companies. The companies reported $931,350 in research payments for these studies, mostly to the institutions running them.
- A single arm open label phase 2 study of tucatinib in combination with trastuzumab deruxtecan in subjects with previously treated unresectable locallyadvanced or metastatic HER2 breast cancer
Pfizer Inc. - CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine …
AstraZeneca UK Limited - SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negativ…
AstraZeneca Pharmaceuticals LP - A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive…
AstraZeneca UK Limited - TOL2506A-EXT
Tolmar, Inc. - A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Re…
E.r. Squibb & Sons, L.l.c. - DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
Daiichi Sankyo Inc. · Completed · NCT03529110 - Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05169567 - DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Daiichi Sankyo Inc. · Completed · NCT03523585 - An openlabel phase 1 study to investigate SGNCEACAM5C in adults with advanced solid tumors
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.